Ribociclib for HR-Positive, Advanced Breast Cancer

被引：16
|
作者：
Araki, Kazuhiro [1 ]
Miyoshi, Yasuo [1 ]
机构：
[1] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 03期
关键词：
KINASE; 4/6; INHIBITOR; PALBOCICLIB; COMBINATION;
D O I：
10.1056/NEJMc1615255
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：288 / 288
页数：1
相关论文
共 50 条
  • [41] A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
    Noguchi, Emi
    Yamanaka, Takashi
    Mukai, Hirofumi
    Yamamoto, Naohito
    Chung, Chi-Feng
    Lu, Yen-Shen
    Chang, Dwan-Ying
    Sohn, Joohyuk
    Kim, Gun Min
    Lee, Kyung-Hun
    Lee, Soo-Chin
    Iwasa, Tsutomu
    Iwata, Hiroji
    Watanabe, Kenichi
    Jung, Kyung Hae
    Tanabe, Yuko
    Kang, Seok Yun
    Yasojima, Hiroyuki
    Aogi, Kenjiro
    Tokunaga, Eriko
    Sim, Sung Hoon
    Yap, Yoon Sim
    Matsumoto, Koji
    Tseng, Ling-Ming
    Umeyama, Yoshiko
    Sudo, Kazuki
    Kojima, Yuki
    Hata, Tomomi
    Kuchiba, Aya
    Shibata, Taro
    Nakamura, Kenichi
    Fujiwara, Yasuhiro
    Tamura, Kenji
    Yonemori, Kan
    NPJ BREAST CANCER, 2024, 10 (01)
  • [42] Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
    Shen, Xia-Bo
    Li, Guang-Liang
    Zheng, Ya-Bing
    Chen, Zhan-Hong
    Cao, Wen-Ming
    Wang, Xiao-Jia
    Shao, Xi-Ying
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [43] Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer
    Fenn, Kathleen M.
    Marks, Douglas K.
    Vanguri, Rami
    Boboila, Shuobo
    Guo, Hua
    Hibshoosh, Hanina
    Kalinsky, Kevin
    Connolly, Eileen
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23):
  • [45] Ribociclib in premenopausal women with advanced breast cancer
    Foukakis, Theodoros
    LANCET ONCOLOGY, 2018, 19 (07): : 850 - 852
  • [46] Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
    Drago, Joshua
    Modi, Shanu
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (01) : 6 - 7
  • [47] Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer
    Wang, Wei
    Liu, Chenghao
    Zhou, Wenbin
    Xia, Tiansong
    Xie, Hui
    Wang, Shui
    SCIENTIFIC REPORTS, 2016, 6
  • [48] Clinical value of Ki67 in risk-stratifying HR-positive breast cancer.
    Bulbul, Ajaz
    Araujo-Mino, Emilio Paul
    Bautista, Adriana
    Rashad, Sadaf
    Khorsand-Sahbaie, Masoud
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Mechanisms of Traditional Chinese medicine/natural medicine in HR-positive Breast Cancer: A comprehensive Literature Review
    Yu, Qinghong
    Xu, Chuchu
    Song, Jiaqing
    Jin, Ying
    Gao, Xiufei
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 319
  • [50] Combination therapy with immune checkpoint inhibitor and targeted agents in metastatic TNBC and HR-positive breast cancer
    Ozaki, Yukinori
    ANNALS OF ONCOLOGY, 2021, 32 : S267 - S267
12345